Polycystic ovary syndrome (PCOS) - risk factor, diagnostic and current treatment
Keywordspolycystic ovary syndrome, PCOS, diagnostics of PCOS, personalized therapy
Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders in women in reproductive age, defined as a combination of signs and symptoms resulting from androgen excess and ovarian dysfunction in the absence of other specific diagnoses. PCOS is often associated with an increased risk of obesity, insulin resistance, metabolic disorders and cardiovascular events.
The aim of the study:
The purpose of this systemic review was to collect and analyze materials about risk factors, diagnostics, and the current treatment of polycystic ovary syndrome.
Material and method:
Review of the literature published in 2004-2018.
Description of the state of knowledge:
PCOS is characterized by an excessive secretion of androgens from the ovaries and / or adrenal glands. Intrinsic ovarian factors, such as altered steroidogenesis, and factors external to the ovary, such as hyperinsulinemia, contribute to the ovarian overproduction of androgens. PCOS requires careful selection of an appropriate diagnostic method and therapeutic approach to combat hyperandrogenism, a consequence of ovarian dysfunction and related metabolic disorders. Treatment of both women at risk of PCOS and those with a confirmed diagnosis of PCOS includes education, healthy lifestyle interventions and symptomatic therapeutic interventions.
PCOS is a complex disorder involving many organs and affecting many body functions. It is important to diagnose this disease as soon as possible in order to implement appropriately selected therapeutic treatment aimed at eliminating disease symptoms and reducing the systemic consequences of hyperandrogenism in patients.
Szydlarska D, Grzesiuk W, Bar-Andziak E, Controversies around pathogenesis polycystic ovary syndrome, 2010, 6(3): 141-146
Crespo, Raiane P, Bachega, Tania ASS, Mendonça, Berenice B, Gomes, Larissa G, An update of genetic basis of PCOS pathogenesis. Archives of Endocrinology and Metabolism 2018, 62(3):352-361.
Patel S, Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy, The Journal of Steroid Biochemistry and Molecular Biology, 2018, 182: 27-36
Barber T, Golding S, Alvey C, Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab. 2008; 93: 999–1004.
Meyer C, McGrath B, Teede H, Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease, J. Clin. Endocrinol. Metab. 2005; 90: 5711– 5716.
Yang O, Kim HL, Weon JI, Seo YR, Endocrine-disrupting chemicals: review of toxicological mechanisms using molecular pathway analysis, J. Cancer Prev., 2015, 20: 12-24
Madnani , Khan K, Chauhan P, Parmar G, Polycystic Ovarian Syndrome, Indian J. Dermatol. Venereol. Leprol., 2013, 79: 310 – 321
Sirmans SM, Pate KA, Epidemiology, diagnosis and treatment of polycystic ovarian syndrome, Clin. Epidemiol., 2013, 6: 1 – 13
Teede H, Deeks A, Moran L, Diamanti-Kandarakis, Kouli C, Bergiele A, Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic symptoms that impacts health throughout life, BMC Med., 2010, 8: 41
Blay SL, Aguiar JVA, Passos IC, Polycystic ovary syndrome and mental disorders: a systematic review and exploratory meta-analysis, Neuropsychiatr. Dis. Treat., 2016, 12: 2895-2903
T.R.E.-S.P.C.W.G.PCOS Consensus Workshop Group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, Fertil. Steril., 2004, 8: 19-25
Piparva KG, Buch JG, Deep vein thrombosis in a woman using combined oral contraceptive pills,J.Pharmacol. Pharmacother. 2011, 2: 185 – 18
Naderpoor N, Shorakae S, Courten B, Misso ML, Moran LJ, Teede HJ, Metformin and lifestyle modification in polycystic ovary syndrome: a systematic review and meta-analysis,Szum. Reprod. Aktualizacja, 2015 , 21: 560 – 574
Davidson R, Motan T, Korownyk C, Clomiphene for anovulatory infertility, Mogą. Fam. Fiz., 2016, 62: 492
How to Cite
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 543
Number of citations: 0